Clinical trial
Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)
NCT05418088 is registered in ClinicalTrials.gov with Sumithira Vasu as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)
- Lead sponsor
- Sumithira Vasu
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- June 30, 2022
- Completion date
- July 1, 2027
- Enrollment
- 54 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent acute lymphoblastic leukemia, recurrent b acute lymphoblastic leukemia, recurrent b-cell prolymphocytic leukemia, recurrent chronic lymphocytic leukemia, recurrent high grade b-cell lymphoma, recurrent indolent non-hodgkin lymphoma, recurrent non-hodgkin lymphoma, recurrent transformed chronic lymphocytic leukemia, refactory childhood acute lymphoblastic leukemia, refractory acute lymphoblastic leukemia, refractory b acute lymphoblastic leukemia, refractory b-cell prolymphocytic leukemia, refractory childhood non-hodgkin lymphoma, refractory chronic lymphocytic leukemia, refractory high grade b-cell lymphoma, refractory indolent non-hodgkin lymphoma, refractory non-hodgkin lymphoma, refractory transformed chronic lymphocytic leukemia